Skip to content
Open access

Ultra-high-field MRI reveals a venous-dominant microbleed phenotype in cerebral amyloid angiopathy: a comparative study versus 3 Tesla MRI.

Aug 2026 · AJNR. American journal of neuroradiology · pp. ajnr.A9578 · 0 citations
Medicine

TL;DR

7T MRI robustly improves CMB detection in CAA and provides higher inter-rater reliability for vCMB classification than 3T, but weak cross-scanner correlation and agreement for the vCMB-to-total ratio preclude interchangeability across field strengths.

Abstract

Background

AND

Purpose

Cerebral microbleeds (CMB) are core MRI markers of cerebral amyloid angiopathy (CAA). Ultra-high-field 7T MRI may improve CMB detection and visualization of venous-associated CMB (vCMB), but the extent to which this reflects additional lesion detection versus field-dependent phenotypic reclassification remains uncertain. We compared CMB burden and venous phenotyping at 7T versus 3T in patients with probable CAA.

Materials And Methods

In this single-center retrospective study, 22 patients with probable CAA underwent paired 3T and 7T MRI within 6 months. Two blinded neuroradiologists assessed total CMB, vCMB, simple/non-venous CMB (sCMB), and the vCMB-to-total ratio on susceptibility-weighted imaging. Paired comparisons used Wilcoxon signed-rank tests; inter-scanner analyses used Spearman correlations and Bland-Altman analysis. Lesion-level distributions were descriptive only because of within-subject clustering.

Results

7T detected more total CMB and vCMB than 3T (1551 versus 818 and 1173 versus 385), whereas sCMB counts did not differ significantly (p = 0.47). The median vCMB-to-total ratio was higher at 7T than at 3T (0.70 versus 0.33; p < 0.001). Inter-scanner correlations were strong for total CMB (r = 0.95) and vCMB count (r = 0.88), but weak and non-significant for the vCMB-to-total ratio (r = 0.32, p = 0.16; n = 21). Inter-rater reliability for the vCMB-to-total ratio was higher at 7T than at 3T (ICC = 0.76 versus 0.54). Cohort-level delta analyses showed that the increase in vCMB approximated the increase in total CMB, whereas the change in sCMB was close to zero.

Conclusion

7T MRI robustly improves CMB detection in CAA and provides higher inter-rater reliability for vCMB classification than 3T. However, weak cross-scanner correlation and agreement for the vCMB-to-total ratio preclude interchangeability across field strengths. The higher 7T vCMB burden is most consistent with additional small-lesion detection, with partial reclassification also possible. 3T remains suitable for global CMB burden assessment, whereas 7T adds value for mechanistic and longitudinal studies. Note: 3T and 7T are retained as standard MRI field-strength designations.

Read PDF

Similar papers

Sep 2026

MRI features and imaging-pathology correlation of oligodendroglioma with IDH mutation and 1p/19q codeletion.

OBJECTIVE To characterize routine magnetic resonance imaging (MRI) manifestations of molecularly defined isocitrate dehydrogenase (IDH)-mutant, 1p/19q codeleted oligodendroglioma, to introduce two newly proposed intratumoral imaging signs, assess their diagnostic efficacy, and interpret their histologic basis via voxel...

Peng-Fei Dong, Dao Zheng, Cong Huang et al. · 0 citations
Sep 2026

Comparative performance of 7T MRI sequences for central vein sign detection in multiple sclerosis: a prospective study.

BACKGROUND The central vein sign (CVS) has been incorporated into the 2024 McDonald criteria for multiple sclerosis (MS) diagnosis. However, the optimal MRI sequence for detecting CVS at 7T remains unclear due to limited direct comparisons. This study aimed to perform a head-to-head comparison of gradient-recalled echo...

Xin-Yao Liu, Ying Yang, Zhe Zhang et al. · 0 citations
Sep 2026

Evaluation of Disease Severity Using CSF Biomarkers in Patients With Probable Cerebral Amyloid Angiopathy.

Findings suggest that CSF Aβ levels may reflect vascular amyloid burden rather than downstream neurodegeneration, and lower CSF Aβ40 and Aβ42 levels are associated with established MRI markers of disease severity, independently of clinical presentation and concomitant Alzheimer-like profile.

Quentin Beaufort, Camille Charbonnier, Philippine Ruellan et al. · 0 citations
Open access Sep 2026

Angioarchitectural Characterization of Target Collateral Vessels in Periventricular Hemorrhagic Moyamoya Disease: A Multimodal 5.0T MRI and DSA Study.

OBJECTIVE The goal of this study was to visualize and characterize the angioarchitecture of the target collateral vessels (TCVs) responsible for periventricular hemorrhage in patients with moyamoya disease (MMD) using a multimodal approach combining ultrahigh-field 5.0T magnetic resonance angiography (MRA) and digital...

Tian-Sheng Qian, Jian Wang, Yu-Jun Liao et al. · 0 citations
Oct 2026

Hyperintense Vessel Sign on High-Resolution Vessel Wall MRI and Perfusion Decompensation in Intracranial Atherosclerotic Disease: Burden Versus Proximal Extent.

RATIONALE AND OBJECTIVES To investigate the relationship between hyperintense vessel sign (HVS) on high-resolution magnetic resonance vessel wall imaging (HR-VWI) and cerebral perfusion decompensation in patients with intracranial atherosclerotic stenosis or occlusion. MATERIALS AND METHODS This retrospective cohort...

F. Ouyang, Qing-Chen Wu, Jie Liu et al. · 0 citations
Open access Sep 2026

Tumor apparent diffusion coefficient combined with the lipid-to-creatine ratio for preoperative differentiation of primary central nervous system lymphoma from high-grade glioma: a single-center diagnostic model development and internal validation study

Background and purpose Primary central nervous system lymphoma (PCNSL) and high-grade glioma (HGG) may share overlapping conventional MRI appearances. We developed and internally validated a parsimonious model combining tumor apparent diffusion coefficient (ADC) and the lipid-to-creatine ratio (Lip/Cr), compared it wit...

Lei Geng, Su-Bo Zhang, Zhao-Ting Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.